Danish Medicines Agency to launch second reimbursement risk-sharing program

On Wednesday, pharmaceutical firms can apply to a trial scheme in Denmark where the public health system and private firms join forces to share the financial risks of expanding certain drug reimbursements.
Photo: Lægemiddelstyrelsen/PR
Photo: Lægemiddelstyrelsen/PR
by mikkel aabenhus hemmingsen, translated by daniel pedersen

The Danish Medicines Agency is ready for another risk-sharing scheme concerning reimbursements for prescription drugs. The original program, which spanned three years and ended in 2021, was aimed at opening reimbursement access for patients in Denmark.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading